A Study to Learn About the Study Medicine Called Tilrekimig in People With Severe Asthma

Part of paid clinical trials in Garland, Texas.

Sponsor: Pfizer
Study ID: NCT07772921
Phase: PHASE3
Status: Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Asthma

Eligibility Criteria

Sex: ALL
Age: 12 Years - 80 Years
Healthy Volunteers: Not accepted

Interventions

tilrekimig — DRUG
subcutaneous injection
Placebo — OTHER
subcutaneous injection

Study Details

The purpose of this clinical study is to learn about the safety and effects of the study medicine (called tilrekimig) for the potential treatment of severe asthma. Asthma is a condition that makes it challenging to breathe, which negatively impacts the quality of life of people who are affected. The study is seeking participants who: * Have a history of severe asthma for at least 12 months * Have had at least 2 asthma attacks (also known as exacerbations) within the last 12 months All participants will be given shots of study medicine or a placebo at the study clinic. The study will compare the experiences of people receiving tilrekimig to those people who receive the placebo. This will help determine if tilrekimig is safe and effective.